Abstract
Concominant neoplasm and abdominal aortic aneurysm (AAA) is not a rare clinical association and can pose problems if antiblastic treatment is required. The literature shows lack of consensus owing to the fact that AAA can modify the liquid load and the hemodynamic setting so that chemotherapy toxicily profile becomes important and hydralion overload increases the AAA-breakage risk. We have analyzed the possibility of treatment with a non-critical water load related chemotherapy in these patients, and if it can offer benefit it terms of overall survival (OS) and quality of life (QL). We concluded thatin chemotherapy the presence of AAA does not have to be excluded first, if such critical parameters such as response to chemotherapy AAA-breakage risk vascular and extravascular toxicity do not compromise the OS and QL of the patients.
| Original language | English |
|---|---|
| Pages (from-to) | 1439-1444 |
| Number of pages | 6 |
| Journal | Anticancer Research |
| Volume | 19 |
| Issue number | 2 B |
| Publication status | Published - 1999 |
Fingerprint
Keywords
- Abdominal aortic aneurysm
- Chemotherapy
- Neoplasm
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Antiblastic chemotherapy in the presence of abdominal aorta aneurysm (AAA) : Guidelines. / Lauro, Salvatore; Lanzetta, Gaetano; Bria, Emilio; Trasatti, Luciana; Gelibter, Alain; Vecchione, Aldo.
In: Anticancer Research, Vol. 19, No. 2 B, 1999, p. 1439-1444.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antiblastic chemotherapy in the presence of abdominal aorta aneurysm (AAA)
T2 - Guidelines
AU - Lauro, Salvatore
AU - Lanzetta, Gaetano
AU - Bria, Emilio
AU - Trasatti, Luciana
AU - Gelibter, Alain
AU - Vecchione, Aldo
PY - 1999
Y1 - 1999
N2 - Concominant neoplasm and abdominal aortic aneurysm (AAA) is not a rare clinical association and can pose problems if antiblastic treatment is required. The literature shows lack of consensus owing to the fact that AAA can modify the liquid load and the hemodynamic setting so that chemotherapy toxicily profile becomes important and hydralion overload increases the AAA-breakage risk. We have analyzed the possibility of treatment with a non-critical water load related chemotherapy in these patients, and if it can offer benefit it terms of overall survival (OS) and quality of life (QL). We concluded thatin chemotherapy the presence of AAA does not have to be excluded first, if such critical parameters such as response to chemotherapy AAA-breakage risk vascular and extravascular toxicity do not compromise the OS and QL of the patients.
AB - Concominant neoplasm and abdominal aortic aneurysm (AAA) is not a rare clinical association and can pose problems if antiblastic treatment is required. The literature shows lack of consensus owing to the fact that AAA can modify the liquid load and the hemodynamic setting so that chemotherapy toxicily profile becomes important and hydralion overload increases the AAA-breakage risk. We have analyzed the possibility of treatment with a non-critical water load related chemotherapy in these patients, and if it can offer benefit it terms of overall survival (OS) and quality of life (QL). We concluded thatin chemotherapy the presence of AAA does not have to be excluded first, if such critical parameters such as response to chemotherapy AAA-breakage risk vascular and extravascular toxicity do not compromise the OS and QL of the patients.
KW - Abdominal aortic aneurysm
KW - Chemotherapy
KW - Neoplasm
UR - http://www.scopus.com/inward/record.url?scp=0032995494&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032995494&partnerID=8YFLogxK
M3 - Article
C2 - 10365120
AN - SCOPUS:0032995494
VL - 19
SP - 1439
EP - 1444
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 2 B
ER -